Date: 2012-12-18
Type of information: Research agreement
Compound: new therapeutic agents against the LRRK2 Parkinson's disease target
Company: Ipsen (France) Oncodesign (France) Laboratory for Neurobiology and Gene Therapy (LNGT - KU Leuven Belgium)
Therapeutic area: Neurodegenerative diseases - CNS diseases
Type agreement: R&D
Action mechanism:
- LRRK2 inhibitor. LRRK2 ((Leucine-Rich Repeat Kinase 2) mutations represent the highest risk of familial PD and are also observed in sporadic patients. Pathological characteristics and clinical symptoms observed in patients carrying LRRK2 mutations are indistinguishable between familial and sporadic patients. LRRK2 is a multidomain protein which contains both GTPase and Kinase enzymatic activities where most pathogenic mutations are located. LRRK2 inhibition represents a potential neuroprotective therapeutic target for the treatment of Parkinson’s disease.
Disease: Parkinson’s disease
Details:
- Oncodesign, a drug discovery company and oncology pharmacology service provider, and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the Department of Neurosciences at the KU Leuven, an expert academic group exploring the roles of LRRK2 and ?-synuclein in Parkinson’s disease headed by Professor Veerle Baekelandt, have entered into a research collaboration to evaluate, with Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease. The collaboration builds on Oncodesign's LRRK2 program with advanced Nanocyclix® lead molecules that was partnered with Ipsen in January 2012. Under the terms of the agreement, Oncodesign and LNGT will closely collaborate to advance Oncodesign's Parkinson’s disease program towards clinical development.
Financial terms:
- LNGT will receive full financial support from Oncodesign for these activities.
Latest news:
Is general: Yes
